Claims for Patent: 4,220,660
✉ Email this page to a colleague
Summary for Patent: 4,220,660
| Title: | Process for the treatment of humans suffering from undesired urotoxic side effects caused by cytostatically active alkylating agents |
| Abstract: | The invention is related to a process for the treatment of humans suffering from undesired urotoxic side effects caused by cytostatically active alkylating agents administered to them against malign tumors, comprising administering a pharmacologically acceptable salt of a mercapto alkane sulfonic acid having the general formula to the human treated with the cytostatically active alkylating agent, in an amount ranging from 20% of the weight of the alkylating agent to the highest tolerated dosage of the salt of the mercapto alkane sulfonic acid, simultaneously or separately in combination with the alkylating agent. |
| Inventor(s): | Brock; Norbert (Bielefeld, DE) |
| Assignee: | Asta-werke Aktiengesellschaft, Chemische Farik (Bielefeld, DE) |
| Application Number: | 05/967,000 |
| Patent Claims: |
1. Process for the treatment of humans suffering from the undesired urotoxic side effects caused by cytostatically active alkylating agents selected from the group consisting of
cyclophosphamide, trofosfamide, ifosfamide, and sufosfamide in the kidneys, urinary tracts and urinary bladder comprising administering a pharmacologically acceptable salt of a mercapto alkane sulfonic acid having the general formula
wherein alk is a member selected from the group consisting of the straight and branched alkylene groups having from 2 to 6 carbon atoms, to the human treated with the alkylating agent in an amount ranging from 20% to about 100% of the weight of the dose of the alkylating agent of the salt of the mercapto alkane sulfonic acid. 2. Process as claimed in claim 1 wherein the salt of the mercapto alkane sulfonic acid is administered to the patient within the period ranging from about 30 minutes before the administration of the cytostatically active alkylating agent up to about 30 minutes after its administration. 3. Process as claimed in claim 1 wherein at least 25% of the total dose of the salt of the mercapto alkane sulfonic acid is administered in a period ranging from about 30 minutes before the administration of the cytostatically active alkylating agent until about 30 minutes after its administration while the remainder of the total dose is administered to the human in a single or in several separate partial doses within a period of up to 12 hours after the administration of the cytostatically active alkylating agent. 4. Process as claimed in claim 1 wherein the salt of the mercapto alkane sulfonic acid is administered to the human in an amount ranging from 30 to 100% of the weight of the dose of the cytostatically active alkylating agent. 5. Process as claimed in claim 1 wherein alk is the 1,2-ethylene group. 6. Process as claimed in claim 1 wherein the pharmacologically acceptable salt of the mercapto alkane sulfonic acid is an alkali metal salt. 7. Process as claimed in claim 6 wherein the pharmacologically acceptable salt is the sodium salt. |
